American College of Cardiology

NOVEMBER 18, 2024

What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27?

Preserved Ejection Fraction 70

Preserved Ejection Fraction BMI Heart Failure Diabetes 70

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased. Overall, 60.9%

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] These individuals tend to have a better prognosis when compared to both individuals with normal weight (BMI of 18.5

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

DAIC

JUNE 26, 2024

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. It also lowered their systolic blood pressure and waist circumference.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105